A Kettering Health patient is the first to enroll in a clinical trial for cancer therapies. The trial will evaluate the efficacy and safety of multiple FDA-approved cancer therapies.

“We are committed to bringing the latest in medical technology and advanced care to the community of patients we serve,” said Dr. Priya Jain, medical oncologist and principal investigator with Kettering Health. “We are proud to be able to offer our patients the chance to enroll in this cutting-edge clinical trial.”

The Strata precision Indications for Approved Therapies (Strata PATH) trial can potentially treat multiple cancers.

The trial will ultimately expand the uses of mutation-specific drugs and potentially give patients more treatment options. Patients with a tumor-tissue mutation will receive FDA-associated treatments approved for the mutation but not their specific cancer. The goal is to see if a drug targeting one cancer mutation can treat all cancers with the same mutation.

Strata PATH will enroll patients with advanced cancer and patients with early-stage cancer who have evidence their cancer has metastasized after initial treatment.